Savara has concluded its Phase I studies of AeroVanc™, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile. We will conduct a Phase IIa trial at multiple sites across the U.S. and Canada. Please check back in the future for details.
AeroVanc phase ISavara has concluded its Phase I studies of AeroVanc™, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile. |
|
AeroVanc Phase IISavara will be enrolling CF patients in a multicenter study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection. The trial will be conducted in 22 sites throughout the U.S. |